{
  "meta": {
    "data_length": 1,
    "message": "Statement id stmt:ema:tremelimumab-astrazeneca:0:4 retrieved successfully",
    "request_url": "https://api.moalmanac.org/statements?statement_id=stmt%3Aema%3Atremelimumab-astrazeneca%3A0%3A4",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.002199,
    "timestamp_received": "2026-10-17T00:35:19.878334+00:00Z",
    "timestamp_returned": "2026-10-17T00:35:19.880533+00:00Z",
    "trace_id": "d11c6097-4ac3-4012-85d1-31758412a8a4"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://moalmanac.org",
    "last_updated": "2026-08-02"
  },
  "data": [
    {
      "id": "stmt:ema:tremelimumab-astrazeneca:0:4",
      "type": "Statement",
      "description": "The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK-positive mutations. This indication is based on POSEIDON, a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",
      "contributions": [
        {
          "id": "ctrb:vanallenlab:2025-09-05:4",
          "type": "Contribution",
          "description": "On 2023-11-06, the European Commission withdrew the market authorization for Tremelimumab AstraZeneca (tremelimumab) in the European Union at the request of the marketing authorization holder, AstraZeneca AB, due to their decision to permanently discontinue the marketing of the product for commercial reasons.",
          "date": "2025-09-05",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        },
        {
          "id": "ctrb:vanallenlab:2024-10-20:0",
          "type": "Contribution",
          "description": "Adding EMA approvals for use to database",
          "date": "2024-10-20",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        },
        {
          "id": "ctrb:ema:2023-02-20:0",
          "type": "Contribution",
          "description": "Indication received approval from the European Commission.",
          "date": "2023-02-20",
          "contributor": {
            "id": "agent:org:ema",
            "type": "Agent",
            "agentType": "organization",
            "name": "European Medicines Agency",
            "description": "Regulatory agency that approves medicines for use in the European Union."
          }
        }
      ],
      "reportedIn": [
        {
          "id": "doc:ema:tremelimumab-astrazeneca",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Tremelimumab AstraZeneca (tremelimumab) [product information]. EMA.",
          "title": null,
          "aliases": [],
          "description": "AstraZeneca AB. Tremelimumab AstraZeneca (tremelimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf. Revised September 2023. Accessed March 25, 2024.",
          "urls": [
            "https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf",
            "https://www.ema.europa.eu/en/medicines/human/EPAR/tremelimumab-astrazeneca"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:ema",
                "type": "Agent",
                "agentType": "organization",
                "name": "European Medicines Agency",
                "description": "Regulatory agency that approves medicines for use in the European Union."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "AstraZeneca AB.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Tremelimumab AstraZeneca",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "tremelimumab",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2023-04-04",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": null,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2024-08-22",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Deprecated",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "direction": "supports",
      "proposition": {
        "id": "prop:vtxr:108",
        "type": "VariantTherapeuticResponseProposition",
        "predicate": "predictsSensitivityTo",
        "subjectVariant": {
          "type": "CategoricalVariant",
          "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition."
        },
        "conditionQualifier": {
          "id": "dis:ncit:C2926",
          "conceptType": "Disease",
          "name": "Non-Small Cell Lung Cancer",
          "mappings": [
            {
              "relation": "exactMatch",
              "coding": {
                "id": "coding:oncotree:NSCLC",
                "code": "NSCLC",
                "name": "Non-Small Cell Lung Cancer",
                "system": "https://oncotree.mskcc.org",
                "systemVersion": "oncotree_2025_10_03",
                "iris": [
                  "https://oncotree.mskcc.org/?version=oncotree_2025_10_03&field=NAME&search=Non-Small+Cell+Lung+Cancer+%28NSCLC%29"
                ]
              }
            }
          ],
          "extensions": [
            {
              "name": "solid_tumor",
              "value": true,
              "description": "Boolean value for if this tumor type is categorized as a solid tumor."
            }
          ],
          "primaryCoding": {
            "id": "coding:ncit:C2926",
            "code": "C2926",
            "name": "Lung Non-Small Cell Carcinoma",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "26.08e",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2926"
            ]
          }
        },
        "objectTherapeutic": {
          "id": "txgrp:24",
          "membershipOperator": "AND",
          "therapies": [
            {
              "id": "tx:ncit:C103194",
              "conceptType": "Therapy",
              "name": "Durvalumab",
              "mappings": [
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "coding:rxcui:1919503",
                    "code": "1919503",
                    "name": "durvalumab",
                    "system": "RxNorm",
                    "systemVersion": "02-Mar-2026",
                    "iris": [
                      "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1919503"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "coding:omop:1594034",
                    "code": "1594034",
                    "name": "durvalumab",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/1594034"
                    ]
                  }
                }
              ],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "PD-1/PD-L1 inhibition"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Immunotherapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ],
              "primaryCoding": {
                "id": "coding:ncit:C103194",
                "code": "C103194",
                "name": "Durvalumab",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "26.08e",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194"
                ]
              }
            },
            {
              "id": "tx:ncit:C49085",
              "conceptType": "Therapy",
              "name": "Tremelimumab",
              "mappings": [
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "coding:rxcui:2619313",
                    "code": "2619313",
                    "name": "tremelimumab",
                    "system": "RxNorm",
                    "systemVersion": "02-Mar-2026",
                    "iris": [
                      "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=2619313"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "coding:omop:741851",
                    "code": "741851",
                    "name": "tremelimumab",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/741851"
                    ]
                  }
                }
              ],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "CTLA-4 inhibition"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Immunotherapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ],
              "primaryCoding": {
                "id": "coding:ncit:C49085",
                "code": "C49085",
                "name": "Tremelimumab",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "26.08e",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49085"
                ]
              }
            },
            {
              "id": "tx:ncit:C2688",
              "conceptType": "Therapy",
              "name": "Nab-paclitaxel",
              "mappings": [
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "coding:rxcui:486610",
                    "code": "486610",
                    "name": "paclitaxel protein-bound",
                    "system": "RxNorm",
                    "systemVersion": "02-Mar-2026",
                    "iris": [
                      "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=486610"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "coding:omop:19112933",
                    "code": "19112933",
                    "name": "paclitaxel protein-bound",
                    "system": "OMOP",
                    "systemVersion": "v20250827",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/19112933"
                    ]
                  }
                }
              ],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "Taxane-based chemotherapy"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Chemotherapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ],
              "primaryCoding": {
                "id": "coding:ncit:C2688",
                "code": "C2688",
                "name": "Nab-paclitaxel",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "26.08e",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2688"
                ]
              }
            },
            {
              "id": "tx:ncit:C1282",
              "conceptType": "Therapy",
              "name": "Carboplatin",
              "mappings": [
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "coding:rxcui:40048",
                    "code": "40048",
                    "name": "carboplatin",
                    "system": "RxNorm",
                    "systemVersion": "20250602",
                    "iris": [
                      "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=40048"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "coding:omop:1344905",
                    "code": "1344905",
                    "name": "carboplatin",
                    "system": "OMOP",
                    "systemVersion": "v20250827",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/1344905"
                    ]
                  }
                }
              ],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "Platinum-based chemotherapy"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Chemotherapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ],
              "primaryCoding": {
                "id": "coding:ncit:C1282",
                "code": "C1282",
                "name": "Carboplatin",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "26.08e",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"
                ]
              }
            }
          ]
        },
        "extensions": [
          {
            "name": "biomarkers",
            "value": [
              {
                "id": "bmkr.criterion:34",
                "present": true,
                "subject": {
                  "id": "bmkr:34",
                  "type": "CategoricalVariant",
                  "name": "Wild type ALK",
                  "constraints": [
                    {
                      "type": "DefiningLocationConstraint",
                      "location": {
                        "id": "ga4gh:SL.o1BcQ-pi-2K5Ga8uf-VSu4ufGNbU6jaZ",
                        "type": "SequenceLocation",
                        "name": null,
                        "aliases": [],
                        "description": "Sequence spanning the length of refseq:NP_004295.2, the protein product of the MANE Select coding transcript for ALK (refseq:NM_004304.5).",
                        "digest": "o1BcQ-pi-2K5Ga8uf-VSu4ufGNbU6jaZ",
                        "sequenceReference": {
                          "id": "ga4gh:SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs",
                          "type": "SequenceReference",
                          "name": "NP_004295.2",
                          "aliases": [
                            "ensembl:ENSP00000373700.3",
                            "ga4gh:SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs",
                            "refseq:NP_004295.2"
                          ],
                          "description": "The protein product of the MANE Select coding transcript for ALK (refseq:NM_004304.5), corresponding to the Refseq protein accession NP_004295.2.",
                          "moleculeType": "protein",
                          "refgetAccession": "SQ.q9CnK-HKWh9eqhOi8FlzR7M0pCmUrWPs",
                          "residueAlphabet": "aa"
                        },
                        "start": 0,
                        "end": 1620,
                        "sequence": null
                      },
                      "relations": [],
                      "matchCharacteristic": {
                        "primaryCoding": {
                          "code": "is_within",
                          "system": "ga4gh-gks-term:location-match"
                        }
                      }
                    },
                    {
                      "type": "FeatureContextConstraint",
                      "featureContext": {
                        "id": "gene:hgnc:427",
                        "conceptType": "Gene",
                        "name": "ALK",
                        "primaryCoding": {
                          "id": "coding:hgnc:427",
                          "code": "HGNC:427",
                          "system": "https://genenames.org",
                          "iris": [
                            "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"
                          ]
                        },
                        "mappings": [
                          {
                            "relation": "exactMatch",
                            "coding": {
                              "id": "coding:ensembl:ensg00000171094",
                              "code": "ENSG00000171094",
                              "system": "https://www.ensembl.org",
                              "iris": [
                                "https://www.ensembl.org/id/ENSG00000171094"
                              ]
                            }
                          },
                          {
                            "relation": "exactMatch",
                            "coding": {
                              "id": "coding:ncbi:238",
                              "code": "238",
                              "system": "https://www.ncbi.nlm.nih.gov/gene",
                              "iris": [
                                "https://www.ncbi.nlm.nih.gov/gene/238"
                              ]
                            }
                          },
                          {
                            "relation": "relatedMatch",
                            "coding": {
                              "id": "coding:refseq:NM_004304.5",
                              "code": "NM_004304.5",
                              "system": "https://www.ncbi.nlm.nih.gov/nuccore",
                              "iris": [
                                "https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"
                              ]
                            }
                          }
                        ]
                      }
                    }
                  ],
                  "extensions": [
                    {
                      "name": "biomarker_type",
                      "value": "Wild type"
                    }
                  ]
                }
              },
              {
                "id": "bmkr.criterion:35",
                "present": true,
                "subject": {
                  "id": "bmkr:35",
                  "type": "CategoricalVariant",
                  "name": "Wild type EGFR",
                  "constraints": [
                    {
                      "type": "DefiningLocationConstraint",
                      "location": {
                        "id": "ga4gh:SL.gJxxJcS0aX-ByerAPT5_YeQKDVk7IZFt",
                        "type": "SequenceLocation",
                        "name": null,
                        "aliases": [],
                        "description": "Sequence spanning the length of refseq:NP_005219.2, the protein product of the MANE Select coding transcript for EGFR (refseq:NM_005228.5).",
                        "digest": "gJxxJcS0aX-ByerAPT5_YeQKDVk7IZFt",
                        "sequenceReference": {
                          "id": "ga4gh:SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE",
                          "type": "SequenceReference",
                          "name": "NP_005219.2",
                          "aliases": [
                            "ensembl:ENSP00000275493.2",
                            "ga4gh:SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE",
                            "refseq:NP_005219.2"
                          ],
                          "description": "The protein product of the MANE Select coding transcript for EGFR (refseq:NM_005228.5), corresponding to the Refseq protein accession NP_005219.2.",
                          "moleculeType": "protein",
                          "refgetAccession": "SQ.vyo55F6mA6n2LgN4cagcdRzOuh38V4mE",
                          "residueAlphabet": "aa"
                        },
                        "start": 0,
                        "end": 1210,
                        "sequence": null
                      },
                      "relations": [],
                      "matchCharacteristic": {
                        "primaryCoding": {
                          "code": "is_within",
                          "system": "ga4gh-gks-term:location-match"
                        }
                      }
                    },
                    {
                      "type": "FeatureContextConstraint",
                      "featureContext": {
                        "id": "gene:hgnc:3236",
                        "conceptType": "Gene",
                        "name": "EGFR",
                        "primaryCoding": {
                          "id": "coding:hgnc:3236",
                          "code": "HGNC:3236",
                          "system": "https://genenames.org",
                          "iris": [
                            "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"
                          ]
                        },
                        "mappings": [
                          {
                            "relation": "exactMatch",
                            "coding": {
                              "id": "coding:ensembl:ensg00000146648",
                              "code": "ENSG00000146648",
                              "system": "https://www.ensembl.org",
                              "iris": [
                                "https://www.ensembl.org/id/ENSG00000146648"
                              ]
                            }
                          },
                          {
                            "relation": "exactMatch",
                            "coding": {
                              "id": "coding:ncbi:1956",
                              "code": "1956",
                              "system": "https://www.ncbi.nlm.nih.gov/gene",
                              "iris": [
                                "https://www.ncbi.nlm.nih.gov/gene/1956"
                              ]
                            }
                          },
                          {
                            "relation": "relatedMatch",
                            "coding": {
                              "id": "coding:refseq:NM_005228.5",
                              "code": "NM_005228.5",
                              "system": "https://www.ncbi.nlm.nih.gov/nuccore",
                              "iris": [
                                "https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"
                              ]
                            }
                          }
                        ]
                      }
                    }
                  ],
                  "extensions": [
                    {
                      "name": "biomarker_type",
                      "value": "Wild type"
                    }
                  ]
                }
              }
            ],
            "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic."
          }
        ]
      },
      "strength": {
        "id": "str:ncit:C25425",
        "conceptType": "Evidence",
        "name": "Approval",
        "mappings": [],
        "primaryCoding": {
          "id": "coding:ncit:C25425",
          "code": "C25425",
          "name": "Approval",
          "system": "https://evsexplore.semantics.cancer.gov",
          "systemVersion": "26.08e",
          "iris": [
            "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425"
          ]
        }
      },
      "extensions": [
        {
          "name": "status",
          "value": "Deprecated",
          "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db."
        },
        {
          "name": "indication",
          "value": {
            "id": "ind:ema:tremelimumab-astrazeneca:0",
            "type": "Indication",
            "description": "Tremelimumab AstraZeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.",
            "contributions": [
              {
                "id": "ctrb:vanallenlab:2025-09-05:4",
                "type": "Contribution",
                "description": "On 2023-11-06, the European Commission withdrew the market authorization for Tremelimumab AstraZeneca (tremelimumab) in the European Union at the request of the marketing authorization holder, AstraZeneca AB, due to their decision to permanently discontinue the marketing of the product for commercial reasons.",
                "date": "2025-09-05",
                "contributor": {
                  "id": "agent:user:vanallenlab",
                  "type": "Agent",
                  "agentType": "contributor",
                  "name": "Van Allen lab",
                  "description": "Van Allen lab, Dana-Farber Cancer Institute"
                }
              },
              {
                "id": "ctrb:vanallenlab:2024-10-20:0",
                "type": "Contribution",
                "description": "Adding EMA approvals for use to database",
                "date": "2024-10-20",
                "contributor": {
                  "id": "agent:user:vanallenlab",
                  "type": "Agent",
                  "agentType": "contributor",
                  "name": "Van Allen lab",
                  "description": "Van Allen lab, Dana-Farber Cancer Institute"
                }
              },
              {
                "id": "ctrb:ema:2023-02-20:0",
                "type": "Contribution",
                "description": "Indication received approval from the European Commission.",
                "date": "2023-02-20",
                "contributor": {
                  "id": "agent:org:ema",
                  "type": "Agent",
                  "agentType": "organization",
                  "name": "European Medicines Agency",
                  "description": "Regulatory agency that approves medicines for use in the European Union."
                }
              }
            ],
            "reportedIn": [
              {
                "id": "doc:ema:tremelimumab-astrazeneca",
                "type": "Document",
                "documentType": "Regulatory approval",
                "name": "Tremelimumab AstraZeneca (tremelimumab) [product information]. EMA.",
                "title": null,
                "aliases": [],
                "description": "AstraZeneca AB. Tremelimumab AstraZeneca (tremelimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf. Revised September 2023. Accessed March 25, 2024.",
                "urls": [
                  "https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf",
                  "https://www.ema.europa.eu/en/medicines/human/EPAR/tremelimumab-astrazeneca"
                ],
                "doi": null,
                "pmid": null,
                "extensions": [
                  {
                    "name": "agent",
                    "value": {
                      "id": "agent:org:ema",
                      "type": "Agent",
                      "agentType": "organization",
                      "name": "European Medicines Agency",
                      "description": "Regulatory agency that approves medicines for use in the European Union."
                    },
                    "description": "The organization that published this document."
                  },
                  {
                    "name": "company",
                    "value": "AstraZeneca AB.",
                    "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
                  },
                  {
                    "name": "drug_name_brand",
                    "value": "Tremelimumab AstraZeneca",
                    "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
                  },
                  {
                    "name": "drug_name_generic",
                    "value": "tremelimumab",
                    "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
                  },
                  {
                    "name": "first_publication_date",
                    "value": "2023-04-04",
                    "description": "The publication date for the initial version of this document."
                  },
                  {
                    "name": "identification_number",
                    "value": null,
                    "description": "Identification number used by the publishing organization."
                  },
                  {
                    "name": "publication_date",
                    "value": "2024-08-22",
                    "description": "The publication date for the document."
                  },
                  {
                    "name": "status",
                    "value": "Deprecated",
                    "description": "Whether this document is Active or Deprecated within moalmanac-db."
                  }
                ]
              }
            ],
            "extensions": [
              {
                "name": "status",
                "value": "Withdrawn",
                "description": "Current approval status."
              }
            ]
          },
          "description": "The underlying Indication supporting this Statement."
        }
      ]
    }
  ]
}